이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nanobiotix 관리

관리 기준 확인 1/4

Nanobiotix's CEO는 Laurent Levy, Mar2003 에 임명되었습니다 의 임기는 21.25 년입니다. 총 연간 보상은 € 3.40M, 12.1% 로 구성됩니다. 12.1% 급여 및 87.9% 보너스(회사 주식 및 옵션 포함). 는 € 4.54M 가치에 해당하는 회사 주식의 2.42% 직접 소유합니다. 4.54M. 경영진과 이사회의 평균 재임 기간은 각각 4.9 년과 1.6 년입니다.

주요 정보

Laurent Levy

최고 경영자

€3.4m

총 보상

CEO 급여 비율	12.1%
CEO 임기	21.3yrs
CEO 소유권	2.4%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	1.7yrs

최근 관리 업데이트

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Dec 22

Recent updates

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 29

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

May 14

CEO 보상 분석

Laurent Levy 의 보수는 Nanobiotix 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	€3m	€411k	-€40m
Sep 30 2023	n/a	n/a	-€49m
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m
Sep 30 2018	n/a	n/a	-€28m
Jun 30 2018	n/a	n/a	-€27m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€861k	€253k	-€26m

보상 대 시장: Laurent 의 총 보상 ($USD 3.65M )은 French 시장( $USD 534.67K ).

보상과 수익: 회사가 수익성이 없는 동안 Laurent 의 보상이 증가했습니다.

CEO

Laurent Levy (51 yo)

21.3yrs

테뉴어

€3,396,084

보상

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

리더십 팀

이름	위치	테뉴어	보상	소유권
Laurent Levy	Co-Founder	21.3yrs	€3.40m	2.42% € 5.7m
Bart Van Rhijn	CFO & Member of Executive Board	3.1yrs	€1.50m	0% € 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	5yrs	€801.96k	0.30% € 700.0k
Louis Kayitalire	Chief Medical Officer	less than a year	€500.80k	데이터 없음
Earl Bergey	Co-Founder	21.5yrs	데이터 없음	데이터 없음
Craig West	Senior Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	데이터 없음	데이터 없음
Patrick Tricoli	Global Head of Business Development	5yrs	데이터 없음	데이터 없음
Margaret Galluzzi	VP & Global Head of Clinical Operations	5.5yrs	데이터 없음	데이터 없음
Ventzislav Vassilev	VP & Global Head of Safety Vigilance	4.2yrs	데이터 없음	데이터 없음
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: NANO 의 관리팀은 노련하고 경험 (평균 재직 기간 5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Enno Spillner	Independent Member of Supervisory Board	10.1yrs	€50.00k	데이터 없음
Gary Phillips	Independent Chairman of Supervisory board	3.2yrs	€63.00k	데이터 없음
Silvia Formenti	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Alain Herrera	Independent Member of Supervisory Board	11.1yrs	€35.00k	데이터 없음
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	10.6yrs	€42.00k	데이터 없음
Hisham Mehanna	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Stephane Champiat	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Jean Bourhis	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Thierry Baere	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Christophe Tourneau	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Nancy Lee	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: NANO 의 이사회는 경험(평균 재직 기간 1.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Nanobiotix 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Recent updates

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

Price target increased by 15% to €25.17

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Price target decreased to €21.90

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Price target decreased to €22.90

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Price target decreased to €23.18

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Price target increased to €29.67

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Consensus EPS estimates fall to -€1.29

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.20

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Price target raised to €25.18

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

New 90-day high: €14.00

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $99 million.

Analysts update estimates